Navigation Links
Excellent Results Received from GeoVax's Full-Dose HIV/AIDS Vaccine Trial
Date:11/2/2007

ATLANTA, Nov. 2 /PRNewswire-FirstCall/ -- GeoVax Labs, Inc. (OTC Bulletin Board: GOVX), an Atlanta based biotechnology company, announced today excellent safety and immunogenicity data from its full-dose HIV/AIDS vaccine human trial which began in September 2006.

This full-dose trial is the second in a series of four Phase 1 human trials designed to test the safety and immunogenicity of the GeoVax HIV/AIDS vaccines. Involving 36 participants of which 30 received vaccine and 6 received placebo, this trial protocol included vaccination with two full-doses of GeoVax's DNA vaccine to prime the immune response followed by two full- doses of GeoVax's MVA vaccine to boost the immune response. GeoVax's DNA and MVA vaccines express over 50% of the AIDS virus (HIV-1) protein components in order to stimulate a broad anti-HIV immune response. The vaccines cannot cause AIDS because they do not include complete virus. A Phase 1 human trial, started in April 2006, evaluated the delivery of only 1/10th of the full dosage and utilized the same vaccine regimen evaluated in the full dose trial.

From data collected from the 26 participants who completed the trial, the following positive conclusions were observed:

-- GeoVax HIV/AIDS vaccines, both DNA and MVA, continue to demonstrate that they are quite safe and immunogenic following the delivery of the four full-doses (two of each vaccine) used in the trial's protocol

-- The full-dose regimen of GeoVax vaccines continues to be well tolerated without any type of reaction, mild or systemic, in the majority of participants

-- CD4 T-cell and CD8 T-cell responses are very evident both in the 1/10th dose and full-dose vaccine recipients

-- Antibody responses to the envelope glycoprotein (Env) increased following the fourth vaccination, and were present in 88% of the full-dose participants

-- Delivery of the fourth vaccination increased the frequency and magnitude of the CD8 T-cell and Antibody
'/>"/>

SOURCE GeoVax Labs, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Biofrontera AG Announces Clinical Study Confirms Excellent Efficacy of BF-200 ALA In Actinic Keratosis
2. Largest Cervical Cancer Vaccine Efficacy Trial Shows Cervarix Provides Excellent Protection Against Lesions Caused by Most Common Cancer-Causing Virus Types
3. Avant’s Typhoid Fever Vaccine Demonstrates Excellent Clinical Potential
4. Avants Typhoid Fever Vaccine Demonstrates Excellent Clinical Potential
5. Point of Care Cardiac Analyzers Yield Rapid Cardiac Marker Results
6. Diagnosing Diabetes: Immediate HbA1c Results Improve Glycemic Control
7. Cell Therapeutics, Inc. Management to Discuss Todays Announcement of Interim Pixantrone Study Results
8. Sygnis Pharma AG announces date for presentation of clinical results
9. Phase 3 Results for Dabigatran Etexilate, an Investigational Oral Anticoagulant, Presented Today at the XXIst Congress of the International Society on Thrombosis and Haemostasis
10. Positive Aggrastat Results Featured in the Journal of the American College of Cardiology
11. Pixantrone Combination Therapy for First-line Treatment of Aggressive Non-Hodgkins Lymphoma Results in Reduction in Severe Toxicities Including Heart Damage When Compared to Doxorubicin-based Therapy
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/24/2014)... 24, 2014 Kinex Pharmaceuticals announced today that ... Roswell Park Cancer Institute. KX2-361 (KX02), a ... has shown potent inhibitory activity against a broad panel ... resistant to Temozolomide (T98G), the most widely used chemotherapy ... brain tumor mouse model, KX2-361 consistently clears brain tumors ...
(Date:12/24/2014)... -- Diplomat Pharmacy, Inc. (NYSE: DPLO ), the ... Jennifer Hagerman , Pharm.D., AE-C, senior director of ... the president of the Michigan Pharmacists Association on Jan. ... Feb. 28, 2015, at the MPA Annual Convention and ... in Detroit, Michigan . Hagerman will ...
(Date:12/24/2014)... 2014 Echo Therapeutics, Inc. (NASDAQ: ... on skin permeation, continuous glucose monitoring and associated ... has been appointed Chief Executive Officer effective ... 20 years of experience in the medical device, ... served as Vice President, Business Development, Otsuka Pharmaceuticals as ...
Breaking Medicine Technology:Kinex Pharmaceuticals Announces First Patient Dosed with KX2-361 in a Phase 1 Clinical Study 2Kinex Pharmaceuticals Announces First Patient Dosed with KX2-361 in a Phase 1 Clinical Study 3Diplomat's senior director of education and quality to be inducted as 2015 president of the Michigan Pharmacists Association 2Diplomat's senior director of education and quality to be inducted as 2015 president of the Michigan Pharmacists Association 3Echo Therapeutics Announces Scott W. Hollander as President & Chief Executive Officer 2Echo Therapeutics Announces Scott W. Hollander as President & Chief Executive Officer 3
... showed patients taking prasugrel had lower ... stroke or cardiovascular death after first event than ... A new,pre-specified analysis of the landmark Phase III ... acute coronary syndromes,(ACS) managed with an artery-opening procedure known ...
... 21 Ardea Biosciences, Inc.,(Nasdaq: RDEA ) today ... in the United Kingdom has authorized a Phase 1,study ... lead product candidate for the treatment of gout., ... 1 study of,RDEA594, within six months from designation as ...
Cached Medicine Technology:Head-to-Head Study Showed Prasugrel Statistically Superior to Clopidogrel in Reducing Recurrent Cardiovascular Events 2Head-to-Head Study Showed Prasugrel Statistically Superior to Clopidogrel in Reducing Recurrent Cardiovascular Events 3Head-to-Head Study Showed Prasugrel Statistically Superior to Clopidogrel in Reducing Recurrent Cardiovascular Events 4Head-to-Head Study Showed Prasugrel Statistically Superior to Clopidogrel in Reducing Recurrent Cardiovascular Events 5Ardea Biosciences Advances Lead Product Candidate for the Treatment of Gout, RDEA594, Into Phase 1 Clinical Trial 2Ardea Biosciences Advances Lead Product Candidate for the Treatment of Gout, RDEA594, Into Phase 1 Clinical Trial 3Ardea Biosciences Advances Lead Product Candidate for the Treatment of Gout, RDEA594, Into Phase 1 Clinical Trial 4
(Date:12/26/2014)... India Network Foundation, a non-profit US ... announced today a new version of “ EasySelect ”, ... right plan for their visiting parents. The technology tool ... selection process when choosing an insurance plan by showing ... a few clicks. Many elderly Asian Indian parents often ...
(Date:12/25/2014)... 26, 2014 This is a professional ... global Sterilizers industry with a focus on the Chinese ... status of the Sterilizers manufacturers and is a valuable ... interested in the industry. This report provides a basic ... manufacturing technology. In this part, the report presents the ...
(Date:12/25/2014)... “Every three months the trends for evening dresses ... will be one of the hottest styles in the next ... the company releases 26 A-line sweetheart evening dresses, and announces ... , “We are trying our best to help a lady ... Along with affordable prices, we provide discounted delivery costs to ...
(Date:12/25/2014)... BambooFlooringChina.com sells many bamboo products and ... Today, the company announces big discounts on its ... colors. , BambooFlooringChina.com is the world’s leader in bamboo ... valid until Jan. 20, 2015. , The bamboo mats ... a natural thread. All the bamboo strips for the ...
(Date:12/25/2014)... Dec. 25, 2014 (HealthDay News) -- The risk of ... holidays, so you need to be extra cautious, an ... we see a significant increase in patients coming in ... the Suffolk County Volunteer Firefighters Burn Center of Stony ... should be full of joy, but if not careful, ...
Breaking Medicine News(10 mins):Health News:India Network Health Insurance Announces new Comprehensive Pre-existing Condition Coverage policy for Visitors to the United States 2Health News:India Network Health Insurance Announces new Comprehensive Pre-existing Condition Coverage policy for Visitors to the United States 3Health News:Sterilizers Industry Global and Chinese Analysis for 2009-2019 Now Available at ReportsnReports.com 2Health News:Sterilizers Industry Global and Chinese Analysis for 2009-2019 Now Available at ReportsnReports.com 3Health News:Various Styles of Bamboo Mats in Many Colors from BambooFlooringChina.com 2Health News:Don't Let Burns Mar Your Holidays 2
... At the 14th annual retrovirus conference in Los Angeles, it ... the United States//. According to Harold Jaffe, a professor of ... no signs of decreasing. ,He also ... fresh infection of HIV cases. Jaffe emphasized on the scientific ...
... to a latest study, the ages at which teenagers and ... a significant impact on their delinquent behavior//. The level of ... earlier than their peer group and vice versa. ... of Youth and Adolescence. Stacy Armour the co-author of this ...
... Inc. today announced the first patient implant in a ... near the spinal cord will control// chronic chest pain ... is the first person to receive this investigational device, ... approximately 1.3 million Americans who suffer from chronic angina, ...
... of Technology researchers have engineered a way to deliver ... as carriers. The breakthrough could lead to low fat ... in fat-containing foods, and could be used to enrich ... ,The team, led by Dr. Yoav ...
... be in gold nanoparticles - tiny pieces of gold so ... potential of gold nanoparticles has been hindered by the difficulty ... be injected into a patient. New research at the University ... used to overcome this problem, creating a new type of ...
... the world's leading pharmaceutical companies, issued a press release ... metastatic prostate cancer. ,A Phase III ... to Novantrone (mitoxantrone) plus prednisone. The study included a ... spread of disease after hormonal therapy., ,The results ...
Cached Medicine News:Health News:Spinal Cord Stimulation Pilot Study for Chronic Angina 2Health News:Natural Milk Protein Could Lead to Super Nutritious Foods 2Health News:Common Ingredient in Big Macs and Sodas Can Stabilize Gold Nanoparticles for Medical Use 2Health News:Common Ingredient in Big Macs and Sodas Can Stabilize Gold Nanoparticles for Medical Use 3
These retractors are packaged singly ready for sterilization at your facility....
These retractors are packaged singly ready for sterilization at your facility....
HemoNIR™ is a portable device that measures the ability of apersons blood to carry oxygen by monitoring functional vs. non functional hemoglobin....
... aureus and methicillin resistant coagulase-negative staphylococci in ... MRSA Latex Kit for PBP2/ detects Penicillin ... Staphylococcus aureus and coagulase-negative staphylococci. PBP2/ is ... and is present in the membranes of ...
Medicine Products: